See more : PennyMac Mortgage Investment Trust (PMT-PA) Income Statement Analysis – Financial Results
Complete financial analysis of PAVmed Inc. (PAVM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PAVmed Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Bharat Heavy Electricals Limited (BHEL.NS) Income Statement Analysis – Financial Results
- ShanDong Cynda Chemical Co.,Ltd (603086.SS) Income Statement Analysis – Financial Results
- Osisko Metals Incorporated (OM.V) Income Statement Analysis – Financial Results
- Eminent Gold Corp. (EMGDF) Income Statement Analysis – Financial Results
- Paymentus Holdings, Inc. (PAY) Income Statement Analysis – Financial Results
PAVmed Inc. (PAVM)
About PAVmed Inc.
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.45M | 377.00K | 500.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 6.42M | 3.61M | 585.00K | 23.00K | 14.23K | 9.79K | 7.11K | 3.79K | 0.00 | 0.00 |
| Gross Profit | -3.97M | -3.24M | -85.00K | -23.00K | -14.23K | -9.79K | -7.11K | -3.79K | 0.00 | 0.00 |
| Gross Profit Ratio | -161.83% | -858.62% | -17.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 14.28M | 25.55M | 19.85M | 10.96M | 6.63M | 4.25M | 2.62M | 1.72M | 489.33K | 22.29K |
| General & Administrative | 30.95M | 41.04M | 25.57M | 12.39M | 7.66M | 6.31M | 5.42M | 3.93M | 1.29M | 0.00 |
| Selling & Marketing | 17.58M | 19.32M | 8.90M | 2.79M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 48.53M | 60.36M | 34.46M | 12.39M | 7.66M | 6.31M | 5.42M | 3.93M | 1.29M | 400.00K |
| Other Expenses | 2.02M | 1.78M | 0.00 | 0.00 | -558.60K | -903.00K | -3.12M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 64.83M | 87.69M | 54.31M | 23.35M | 14.30M | 10.56M | 8.03M | 5.65M | 1.78M | 548.77K |
| Cost & Expenses | 71.25M | 91.30M | 54.89M | 23.35M | 14.30M | 10.56M | 8.03M | 5.65M | 1.78M | 548.77K |
| Interest Income | 505.00K | 1.27M | 0.00 | 53.00K | 33.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 589.00K | 1.27M | 0.00 | 53.00K | 32.67K | 2.39M | 724.68K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.93M | 2.55M | 226.00K | 23.00K | 14.23K | 9.79K | 7.11K | 3.79K | 1.78M | 422.29K |
| EBITDA | -75.74M | -99.41M | -55.90M | -35.81M | -16.67M | -12.07M | -11.15M | -5.65M | -1.78M | -126.48K |
| EBITDA Ratio | -3,088.99% | -24,615.92% | -10,833.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -68.80M | -90.93M | -54.39M | -23.35M | -14.30M | -10.56M | -8.03M | -5.65M | -1.78M | -422.29K |
| Operating Income Ratio | -2,805.67% | -24,118.57% | -10,878.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -10.47M | -12.15M | -1.73M | -12.54M | -2.97M | -7.61M | -1.49M | 0.00 | 0.00 | -126.48K |
| Income Before Tax | -79.26M | -103.24M | -56.13M | -35.89M | -17.27M | -18.17M | -9.52M | -5.65M | -1.78M | -548.77K |
| Income Before Tax Ratio | -3,232.59% | -27,384.08% | -11,225.20% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.94M | -5.78M | -1.56M | -1.34M | -204.07K | 878.87K | -1.00 | -1.78M | -126.48K |
| Net Income | -64.18M | -101.29M | -50.35M | -34.33M | -15.93M | -17.97M | -9.52M | -5.65M | -1.78M | -548.77K |
| Net Income Ratio | -2,617.25% | -26,868.44% | -10,069.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -9.16 | -15.03 | -9.80 | -10.93 | -8.31 | -12.63 | -11.56 | -6.53 | -2.36 | -0.96 |
| EPS Diluted | -9.16 | -15.03 | -9.80 | -10.93 | -8.31 | -12.63 | -11.56 | -6.53 | -2.36 | -0.96 |
| Weighted Avg Shares Out | 7.23M | 5.94M | 5.17M | 3.16M | 2.01M | 1.49M | 899.73K | 864.81K | 751.92K | 574.55K |
| Weighted Avg Shares Out (Dil) | 7.23M | 5.94M | 5.17M | 3.16M | 2.01M | 1.49M | 899.73K | 864.81K | 751.92K | 574.55K |
PAVmed Inc. (PAVM) Q2 2023 Earnings Call Transcript
PAVmed Inc. (NASDAQ:PAVM ) Q2 2023 Earnings Conference Call August 16, 2023 8:30 AM ET Company Participants Michael Parks - Vice President of Investor Relations Lishan Aklog - Chairman and Chief Executive Officer Dennis McGrath - Executive Vice President and...
PAVmed Provides Business Update and Second Quarter Financial Results
EsoGuard® test volume continues to grow as Lucid makes strides with commercial expansion and additional supporting data Veris Health prepares to launch the next generation of the Veris Cancer Care Platform along with strategic initiatives to develop a biopharma companion...
PAVmed to Hold a Business Update Conference Call and Webcast on August 16, 2023
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , July 31, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital...
Lucid Diagnostics to Present at the Canaccord Genuity 43rd Annual Growth Conference
NEW YORK , July 26, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid Diagnostics" or "Lucid"), a commercial-stage cancer prevention diagnostics company and a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that Shaun O'Neil, Executive Vice President...
PAVmed and Lucid Chairman and Chief Executive Officer, Dr. Lishan Aklog, Testifies at U.S. House of Representatives Energy and Commerce Committee, Hearing on Life-Saving Innovations and Medicare Coverage
Advocated stronger transparency and predictability, and inclusion of diagnostics, in federal proposals to improve equitable access to innovative lifesaving technologies Highlighted EsoGuard's life-saving potential, and unprecedented early detection results of a recently posted NCI-supported EsoGuard study NEW YORK , July...
PAVmed Receives 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement
NEW YORK , June 28, 2023 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it received a written...
Lucid Diagnostics Launches First EsoGuard® Mobile Test Unit
First esophageal precancer detection event utilizing an EsoGuard mobile test unit to be hosted today by Florida Digestive Health Specialists in Sarasota, Florida NEW YORK , June 5, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid Diagnostics" or "Lucid"),...
PAVmed Digital Health Subsidiary, Veris Health, Joins Cancer Moonshot's CancerX Partnership as Founding Member
NEW YORK , June 2, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc. ("Veris"),...
3 Biotech Stocks That Could Turn $1,000 into $10,000 by 2024
Developing groundbreaking drugs and devices entails high costs, uncertain regulatory approval, and lucrative revenues. Those factors and more culminate to create a sector filled with dozens of biotech stocks that have 10X potential, or better.
PAVmed Provides Business Update and First Quarter Financial Results
EsoGuard® test volume gains momentum as Lucid expands high-volume testing events PAVmed appoints President for Veris Health and expands commercial footprint Conference call and webcast to be held tomorrow, May 17 th at 8:30 AM EST NEW YORK , May...
Source: https://incomestatements.info
Category: Stock Reports